



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Idiopathic Pulmonary Fibrosis Therapy (Esbriet, Ofev)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:		* Date of Birth:
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b> <input type="checkbox"/> Standard <span style="margin-left: 200px;"><input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)</span>					
<b>Medication requested</b> <input type="checkbox"/> Esbriet 267mg <input type="checkbox"/> Esbriet 801mg <input type="checkbox"/> Ofev 100mg <input type="checkbox"/> Ofev 150mg    ICD10: _____ Directions for use: _____    Quantity: _____    Duration of therapy: _____ Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose new start of therapy. <input type="checkbox"/> new start of therapy <input type="checkbox"/> continued therapy (if continued therapy) Has your patient had a beneficial clinical response to therapy with this drug? <input type="checkbox"/> Yes <input type="checkbox"/> No or Unknown (if no) Please provide clinical support for continued use of this drug.					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span>					
<b>Diagnosis related to use:</b> <input type="checkbox"/> idiopathic pulmonary fibrosis (IPF) <span style="float: right;">(ICD10 J84.112)</span> <input type="checkbox"/> interstitial lung diseases (ILDs) <input type="checkbox"/> systemic sclerosis-associated interstitial lung disease (SSc-ILD) <input type="checkbox"/> Other (please specify): _____					
<b>Clinical Information:</b> (if Ofev for ILDs) Does the patient have chronic fibrosing interstitial lung diseases (ILDs) with progression? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Ofev for SSc-ILD) Does the patient have the documented diagnosis of systemic sclerosis (SSc)? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Idiopathic Pulmonary Fibrosis) Have other potential causes of interstitial lung disease (for example, medication use, environmental exposures at home/work) been excluded? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Idiopathic Pulmonary Fibrosis) Has the patient had a high-resolution CT scan (HRCT) scan with results showing a pattern that meets BOTH criteria for usual interstitial pneumonia (UIP): A) Subpleural and basal predominant distribution; -AND- B) Honeycombing with or without peripheral traction bronchiectasis or bronchiolectasis? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Idiopathic Pulmonary Fibrosis) Has the patient had a lung biopsy with pathology confirming UIP? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Idiopathic Pulmonary Fibrosis) Has the patient had a HRCT scan AND a lung biopsy and BOTH are indicative of probable UIP? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Ofev for ILDs/SSc-ILD) Does the patient have documentation of interstitial fibrosing lung disease on high-resolution computed tomography (HRCT)? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if Ofev for ILDs) Does the patient have clinical signs of progression evidenced by a forced vital capacity decline of at least 10% of the predicted value? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span> (if no) Does the patient have clinical signs of progression evidenced by a forced vital capacity decline from 5% to less than 10% with worsening symptoms and/or worsening imaging? <span style="float: right;"><input type="checkbox"/> Yes    <input type="checkbox"/> No</span>					

**\*\*\*Please include documentation to support the above 8 questions (including chart notes, test results, etc)**

(if Ofev for SSc-ILD and new to therapy) Is this drug being prescribed by, or in consultation with, a pulmonologist or a rheumatologist?

Yes  No

(if Esbriet for IPF or if Ofev for IPF/ILDs or SSc-ILD established pt only) Is this drug being prescribed by, or in consultation with, a pulmonologist?

Yes  No

Will your patient be using Ofev and Esbriet together?

Yes  No

**Additional Pertinent Information:** *(examples could include past medications tried, labs, pertinent patient history):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v060120

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005